Lorin A Ferris
Overview
Explore the profile of Lorin A Ferris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
675
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wong R, Ferris L, Do O, Holt S, Ramos J, Crabb S, et al.
Oncologist
. 2021 Aug;
26(12):1026-1034.
PMID: 34355457
Background: Fit patients with metastatic urothelial carcinoma (mUC) receive first-line platinum-based combination chemotherapy (fPBC) as standard of care and may receive additional later-line chemotherapy after progression. Our study compares outcomes...
2.
Do O, Ferris L, Holt S, Ramos J, Harshman L, Plimack E, et al.
Clin Genitourin Cancer
. 2020 Dec;
19(2):125-134.
PMID: 33309564
Background: Optimal chemotherapy for patients who received cisplatin for localized urothelial carcinoma (UC) and develop metastatic disease is unclear. We compared the efficacy of platinum-based (PBC) versus non-platinum-based (NPBC) first-line...
3.
Dagogo-Jack I, Rooney M, Nagy R, Lin J, Chin E, Ferris L, et al.
J Thorac Oncol
. 2019 Jan;
14(5):816-824.
PMID: 30664990
Introduction: Circulating tumor DNA analysis is an emerging genotyping strategy that can identify tumor-specific genetic alterations in plasma including mutations and rearrangements. Detection of ROS1 fusions in plasma requires genotyping...
4.
Nangia V, Siddiqui F, Caenepeel S, Timonina D, Bilton S, Phan N, et al.
Cancer Discov
. 2018 Sep;
8(12):1598-1613.
PMID: 30254092
BH3 mimetic drugs, which inhibit prosurvival BCL2 family proteins, have limited single-agent activity in solid tumor models. The potential of BH3 mimetics for these cancers may depend on their ability...
5.
Dagogo-Jack I, Martinez P, Yeap B, Ambrogio C, Ferris L, Lydon C, et al.
Clin Cancer Res
. 2018 Sep;
25(1):158-165.
PMID: 30224342
Purpose: mutations are divided into functional classes distinguished by signaling mechanism and kinase activity: V600-mutant kinase-activating monomers (class I), kinase-activating dimers (class II), and kinase-inactivating heterodimers (class III). The relationship...
6.
Lin J, Chin E, Yeap B, Ferris L, Kamesan V, Lennes I, et al.
J Thorac Oncol
. 2018 Sep;
14(1):135-140.
PMID: 30205166
Introduction: Immune checkpoint inhibitors (ICIs) are standard therapies in advanced NSCLC. Although genotype-directed tyrosine kinase inhibitors represent the standard of care for subsets of oncogene-driven NSCLC, patients may receive ICIs...
7.
Lin J, Zhu V, Schoenfeld A, Yeap B, Saxena A, Ferris L, et al.
J Thorac Oncol
. 2018 Jun;
13(10):1530-1538.
PMID: 29935304
Introduction: The second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib recently showed superior efficacy compared to the first-generation ALK inhibitor crizotinib in advanced ALK-rearranged NSCLC, establishing alectinib as the new standard...
8.
Yoda S, Lin J, Lawrence M, Burke B, Friboulet L, Langenbucher A, et al.
Cancer Discov
. 2018 Apr;
8(6):714-729.
PMID: 29650534
The cornerstone of treatment for advanced ALK-positive lung cancer is sequential therapy with increasingly potent and selective ALK inhibitors. The third-generation ALK inhibitor lorlatinib has demonstrated clinical activity in patients...
9.
Dagogo-Jack I, Brannon A, Ferris L, Campbell C, Lin J, Schultz K, et al.
JCO Precis Oncol
. 2018 Jan;
2018.
PMID: 29376144
Purpose: rearrangements predict for sensitivity to ALK tyrosine kinase inhibitors (TKIs). However, responses to ALK TKIs are generally short-lived. Serial molecular analysis is an informative strategy for identifying genetic mediators...
10.
Gainor J, Tseng D, Yoda S, Dagogo-Jack I, Friboulet L, Lin J, et al.
JCO Precis Oncol
. 2018 Jan;
2017.
PMID: 29333528
Purpose: The ROS1 tyrosine kinase is activated through gene rearrangements in 1-2% of non-small cell lung cancer (NSCLC), conferring sensitivity to treatment with the ALK/ROS1/MET inhibitor crizotinib. Currently, insights into...